Compare Goldman Sachs Group Inc (GS) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Tilray Brands Inc — how do they compare? Goldman Sachs Group Inc trades at $1,114.62 (market cap $339.87B), while Tilray Brands Inc trades at $4.38 (market cap $541.36M). The key difference: Goldman Sachs Group Inc is far larger — about 627.8× Tilray Brands Inc's market cap, and Goldman Sachs Group Inc pays a 1.56% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| GS | TLRY | |
|---|---|---|
Market Cap | $339.87B | $541.36M |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $21.00 |
52-Week Low | $700.41 | $4.31 |
Dividend Yield | 1.56% | — |
Enterprise Value | — | $638.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,140, up 9.0% over 24 hours, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $20.98 versus $14.47, and revenue growth from $58.28B in 2025 to $60.4B projected for 2026. Recent news highlights Goldman's role in leading high-profile IPOs including Anthropic, signaling strong investment banking pipeline strength.
Outlook remains positive with analyst consensus price target of $1,140K and 40% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include volatile cash flow patterns and high leverage, while institutional sentiment supports continued growth from M&A activity and AI-driven market opportunities.
TLRY trades at $4.355, down 0.57% on the day, amid a bearish technical signal and weak earnings performance. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, while revenue grew to $821.31 million. Recent news includes medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.
The outlook remains challenging due to persistent losses and high debt levels, though low valuation ratios like P/S of 0.55 and P/B of 0.35 may attract value investors. Key risks include profitability struggles, regulatory uncertainty, and competitive pressures in the cannabis sector. Analyst sentiment is mixed, with 65% hold ratings reflecting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
